McAfee sees upside in Dr Solomon's flotation

McAfee Associates today said it welcomed arch-rival Dr Solomon's plans to seek a public flotation.

Jeff Barnes, UK country manager of McAfee said the move would force Dr Solomon's UK customers into reconsidering its choice of anti-virus and security products. "It will force them to report their real financial position," Barnes said. "The key factors people look for in a hi-tech stock are profitability, revenue growth and profit per employee. Nobody knows what they are [for Dr Solomon's] at the moment. The things they will need to do to get a good return for their investors could leave them hamstrung on the investment in research and development and the other things they need to do to stay ahead of the game."

"Certainly for corporate accounts looking for a solid supplier this will be interesting. When you're a public company all your washing is laid out for everybody to see and some of it is dirty."

"For a one-product company they are doing okay but there are only two ways to grow: by investment in R&D or by buying other companies. We have moved successfully into network management and security to the extent that anti-virus is just one of the things that we do. It remains to be seen whether Dr Solomon's can do the same."